Logos Global Management LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 17, 2026), Logos Global Management LP reported 63 stock positions worth $1.5 billion. Its top holding was Revolution Medicines (RVMD) at 10.6% of the portfolio, followed by Praxis Precision Medicines I (PRAX, 7.4%) and Ideaya Biosciences (IDYA, 7.2%). Compared with Q3 2025, it opened 22 new positions, sold out of 11, added to 15 and reduced 20. The biggest buy was Praxis Precision Medicines I (PRAX, shares +200%) and the biggest sale an exit from Akero Therapeutics (AKRO).
- Most Recent 13F
- Q2 2026
- Location
- San Francisco, CA
- CIK
- 0001792126
- Portfolio Value
- $1.5B (Q4 2025)
- SEC Filing
- 0001172661-26-001209 ↗ filed Feb 17, 2026
Holdings Value
Holdings 63 stocks · $1.5B
| RVMD Revolution Medicines Inc. | 10.62% | 2,000,000 | $159.3M | Add +14.3% |
| PRAX Praxis Precision Medicines I | 7.37% | 375,000 | $110.5M | Add +200.0% |
| IDYA Ideaya Biosciences Inc. | 7.20% | 3,125,000 | $108.0M | Add +38.9% |
| OLMA Olema Pharmaceuticals Inc. | 5.35% | 3,208,875 | $80.2M | No change |
| CDTX Cidara Therapeutics Inc. | 4.56% | 310,000 | $68.5M | Reduce -17.3% |
| ABVX Abivax SA-ADR | 3.59% | 400,000 | $53.9M | Reduce -3.6% |
| ERAS Erasca Inc. | 3.22% | 13,000,000 | $48.4M | Reduce -14.2% |
| OCUL Ocular Therapeutix Inc. | 2.83% | 3,500,000 | $42.5M | Add +7.7% |
| GPCR Structure Therapeutics Inc. | 2.78% | 600,000 | $41.7M | Reduce -29.4% |
| IRON Disc Medicine Inc. | 2.70% | 510,000 | $40.5M | Add +13.3% |
| MAZE Maze Therapeutics Inc. | 2.62% | 950,000 | $39.4M | Reduce -22.6% |
| TNGX Tango Therapeutics Inc. | 2.48% | 4,200,000 | $37.2M | Add +342.1% |
| RNAM Avidity Biosciences Inc. | 2.40% | 500,000 | $36.1M | Reduce -16.7% |
| BIIB Biogen Inc. | 2.35% | 200,000 | $35.2M | Add +100.0% |
| IMVT Immunovant Inc. | 2.33% | 1,375,000 | $35.0M | Add +400.0% |
| JAZZ Jazz Pharmaceuticals PLC | 2.27% | 200,000 | $34.0M | No change |
| TERN Terns Pharmaceuticals Inc. | 2.02% | 750,000 | $30.3M | New |
| PCVX Vaxcyte Inc. | 2.00% | 650,000 | $30.0M | Add +4.0% |
| IMCR Immunocore Holdings PLC-ADR | 1.97% | 850,000 | $29.5M | No change |
| LBRX LB Pharmaceuticals Inc. | 1.78% | 1,200,000 | $26.7M | Add +6.2% |
| DYN Dyne Therapeutics Inc. | 1.63% | 1,250,000 | $24.4M | Reduce -47.9% |
| DSGN Design Therapeutics Inc. | 1.56% | 2,500,000 | $23.4M | Reduce -31.6% |
| MLTX Moonlake Immunotherapeutics | 1.54% | 1,750,000 | $23.1M | New |
| ACAD Acadia Pharmaceuticals Inc. | 1.51% | 850,000 | $22.7M | New |
| RYTM Rhythm Pharmaceuticals Inc. | 1.36% | 190,000 | $20.3M | Reduce -5.0% |
| TRVI Trevi Therapeutics Inc. | 1.29% | 1,550,000 | $19.4M | Reduce -29.6% |
| CYTK Cytokinetics Inc. | 1.27% | 300,000 | $19.1M | New |
| MIRM Mirum Pharmaceuticals Inc. | 1.18% | 225,000 | $17.8M | New |
| QURE Uniqure NV | 1.08% | 675,000 | $16.2M | Add +125.0% |
| NAMS Newamsterdam Pharma Co. NV | 1.05% | 450,000 | $15.8M | New |
| KNSA Kiniksa Pharmaceuticals Inte | 0.96% | 350,000 | $14.4M | New |
| SLNO Soleno Therapeutics Inc. | 0.93% | 300,000 | $13.9M | New |
| JANX Janux Therapeutics Inc. | 0.92% | 1,000,000 | $13.8M | Add +7.0% |
| NERV Minerva Neurosciences Inc. | 0.89% | 3,311,000 | $13.3M | New |
| VSTM Verastem Inc. | 0.87% | 1,700,000 | $13.1M | Reduce -58.0% |
| DNTH Dianthus Therapeutics Inc. | 0.86% | 315,000 | $13.0M | Add +57.5% |
| AMLX Amylyx Pharmaceuticals Inc. | 0.76% | 950,000 | $11.5M | Reduce -34.5% |
| KYMR Kymera Therapeutics Inc. | 0.67% | 130,000 | $10.1M | Reduce -48.0% |
| CLDX Celldex Therapeutics Inc. | 0.63% | 350,000 | $9.5M | New |
| NRIX Nurix Therapeutics Inc. | 0.63% | 500,000 | $9.5M | New |
| CGON CG Oncology Inc. | 0.55% | 200,000 | $8.3M | New |
| ACLX Arcellx Inc. | 0.50% | 115,000 | $7.5M | Reduce -30.3% |
| CBIO Crescent Biopharma Inc. | 0.47% | 600,000 | $7.1M | No change |
| CMPX Compass Therapeutics Inc. | 0.41% | 1,150,000 | $6.2M | Reduce -43.9% |
| JBIO Jade Biosciences Inc. | 0.41% | 395,000 | $6.1M | Reduce -36.8% |
| TYRA Tyra Biosciences Inc. | 0.37% | 210,000 | $5.5M | New |
| ELVN Enliven Therapeutics Inc. | 0.35% | 340,000 | $5.2M | No change |
| IMMX Immix Biopharma Inc. | 0.35% | 1,000,000 | $5.2M | New |
| CNTA Centessa Pharmaceuticals Ltd. | 0.33% | 200,000 | $5.0M | Reduce -61.9% |
| NGNE Neurogene Inc. | 0.27% | 195,000 | $4.0M | New |
| IBIO Ibio Inc. | 0.26% | 2,000,000 | $3.9M | New |
| CRVS Corvus Pharmaceuticals Inc. | 0.26% | 500,000 | $3.9M | New |
| ORIC Oric Pharmaceuticals Inc. | 0.25% | 450,000 | $3.7M | New |
| DAWN Day One Biopharmaceuticals I | 0.19% | 300,000 | $2.8M | New |
| PHVS Pharvaris NV | 0.18% | 100,000 | $2.8M | Reduce -33.3% |
| UNCY Unicycive Therapeutics Inc. | 0.18% | 473,563 | $2.7M | No change |
| GUTS Fractyl Health Inc. | 0.16% | 1,100,000 | $2.4M | Add +120.0% |
| PTN Palatin Technologies Inc. | 0.14% | 140,000 | $2.2M | New |
| ACRS Aclaris Therapeutics Inc. | 0.12% | 600,000 | $1.8M | Reduce -60.0% |
| VOR Vor Biopharma Inc. | 0.09% | 100,000 | $1.3M | New |
| MREO Mereo Biopharma Group PL-ADR | 0.05% | 1,850,000 | $771K | Add +270.0% |
| SEPN Septerna Inc. | 0.04% | 23,548 | $657K | Reduce -71.8% |
| DBVT DBV Technologies SA-Spon ADR | 0.03% | 25,000 | $479K | New |
Options reported separately and not counted above: RVMD calls ($79.7M), APLS calls ($25.1M), RCUS calls ($25.0M), IDYA calls ($15.6M), IMTX calls ($8.9M).
Other holdings (1): bonds, preferreds, convertibles and warrants · $22K (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| NUVB.WS Nuvation Bio Inc. -CW27 | *W EXP 02/10/202 | 66,666 | $22K | No change |
Total filed on the 13F, all lines: $1.5B.
Portfolio Sells Q3 2025 → Q4 2025
| AKRO Akero Therapeutics Inc. | Sold out | 0.00% | −5.63 |
| ARVN Arvinas Inc. | Sold out | 0.00% | −4.69 |
| VSTM Verastem Inc. | Reduce -58.0% | 0.87% | −2.66 |
| PTGX Protagonist Therapeutics Inc. | Sold out | 0.00% | −1.97 |
| DYN Dyne Therapeutics Inc. | Reduce -47.9% | 1.63% | −1.37 |
| KROS Keros Therapeutics Inc. | Sold out | 0.00% | −1.33 |
| AMLX Amylyx Pharmaceuticals Inc. | Reduce -34.5% | 0.76% | −1.18 |
| DSGN Design Therapeutics Inc. | Reduce -31.6% | 1.56% | −1.16 |
| CNTA Centessa Pharmaceuticals Ltd. | Reduce -61.9% | 0.33% | −0.92 |
| ACLX Arcellx Inc. | Reduce -30.3% | 0.50% | −0.84 |
| KYMR Kymera Therapeutics Inc. | Reduce -48.0% | 0.67% | −0.72 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −0.71 |
| TRVI Trevi Therapeutics Inc. | Reduce -29.6% | 1.29% | −0.70 |
| IMRX Immuneering Corp. Class A | Sold out | 0.00% | −0.66 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −0.64 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -5.0% | 1.36% | −0.64 |
| EPRX Eupraxia Pharmaceuticals Inc. | Sold out | 0.00% | −0.52 |
| MAZE Maze Therapeutics Inc. | Reduce -22.6% | 2.62% | −0.52 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.36 |
| PEPG Pepgen Inc. | Sold out | 0.00% | −0.34 |
| CMPX Compass Therapeutics Inc. | Reduce -43.9% | 0.41% | −0.30 |
| ESPR Esperion Therapeutics Inc. | Sold out | 0.00% | −0.20 |
| PHVS Pharvaris NV | Reduce -33.3% | 0.18% | −0.18 |
| RNAM Avidity Biosciences Inc. | Reduce -16.7% | 2.40% | −0.18 |
| ACRS Aclaris Therapeutics Inc. | Reduce -60.0% | 0.12% | −0.16 |
| JBIO Jade Biosciences Inc. | Reduce -36.8% | 0.41% | −0.13 |
| SEPN Septerna Inc. | Reduce -71.8% | 0.04% | −0.11 |
| ERAS Erasca Inc. | Reduce -14.2% | 3.22% | −0.04 |
| ABVX Abivax SA-ADR | Reduce -3.6% | 3.59% | +0.11 |
| GPCR Structure Therapeutics Inc. | Reduce -29.4% | 2.78% | +0.43 |
| CDTX Cidara Therapeutics Inc. | Reduce -17.3% | 4.56% | +1.02 |
Portfolio Buys Q3 2025 → Q4 2025
| PRAX Praxis Precision Medicines I | Add +200.0% | 7.37% | +6.71 |
| RVMD Revolution Medicines Inc. | Add +14.3% | 10.62% | +2.54 |
| TERN Terns Pharmaceuticals Inc. | New | 2.02% | +2.02 |
| IMVT Immunovant Inc. | Add +400.0% | 2.33% | +1.89 |
| TNGX Tango Therapeutics Inc. | Add +342.1% | 2.48% | +1.69 |
| MLTX Moonlake Immunotherapeutics | New | 1.54% | +1.54 |
| ACAD Acadia Pharmaceuticals Inc. | New | 1.51% | +1.51 |
| CYTK Cytokinetics Inc. | New | 1.27% | +1.27 |
| MIRM Mirum Pharmaceuticals Inc. | New | 1.18% | +1.18 |
| IDYA Ideaya Biosciences Inc. | Add +38.9% | 7.20% | +1.15 |
| NAMS Newamsterdam Pharma Co. NV | New | 1.05% | +1.05 |
| KNSA Kiniksa Pharmaceuticals Inte | New | 0.96% | +0.96 |
| BIIB Biogen Inc. | Add +100.0% | 2.35% | +0.96 |
| SLNO Soleno Therapeutics Inc. | New | 0.93% | +0.93 |
| NERV Minerva Neurosciences Inc. | New | 0.89% | +0.89 |
| CLDX Celldex Therapeutics Inc. | New | 0.63% | +0.63 |
| NRIX Nurix Therapeutics Inc. | New | 0.63% | +0.63 |
| CGON CG Oncology Inc. | New | 0.55% | +0.55 |
| TYRA Tyra Biosciences Inc. | New | 0.37% | +0.37 |
| IMMX Immix Biopharma Inc. | New | 0.35% | +0.35 |
| NGNE Neurogene Inc. | New | 0.27% | +0.27 |
| IBIO Ibio Inc. | New | 0.26% | +0.26 |
| CRVS Corvus Pharmaceuticals Inc. | New | 0.26% | +0.26 |
| ORIC Oric Pharmaceuticals Inc. | New | 0.25% | +0.25 |
| DAWN Day One Biopharmaceuticals I | New | 0.19% | +0.19 |
| PTN Palatin Technologies Inc. | New | 0.14% | +0.14 |
| DNTH Dianthus Therapeutics Inc. | Add +57.5% | 0.86% | +0.09 |
| VOR Vor Biopharma Inc. | New | 0.09% | +0.09 |
| GUTS Fractyl Health Inc. | Add +120.0% | 0.16% | +0.08 |
| DBVT DBV Technologies SA-Spon ADR | New | 0.03% | +0.03 |
| LBRX LB Pharmaceuticals Inc. | Add +6.2% | 1.78% | +0.02 |
| MREO Mereo Biopharma Group PL-ADR | Add +270.0% | 0.05% | −0.05 |
| PCVX Vaxcyte Inc. | Add +4.0% | 2.00% | −0.23 |
| IRON Disc Medicine Inc. | Add +13.3% | 2.70% | −0.24 |
| QURE Uniqure NV | Add +125.0% | 1.08% | −0.65 |
| OCUL Ocular Therapeutix Inc. | Add +7.7% | 2.83% | −0.92 |
| JANX Janux Therapeutics Inc. | Add +7.0% | 0.92% | −1.34 |
Options Activity Q3 2025 → Q4 2025
| RCUS Arcus Biosciences Inc. | call | New | 1,050,000 | $25.0M |
| JANX Janux Therapeutics Inc. | call | Sold out | 500,000 | $12.2Mbefore exit |
| IMTX Immatics NV | call | New | 850,000 | $8.9M |
| LRMR Larimar Therapeutics Inc. | call | Sold out | 2,500,000 | $8.1Mbefore exit |
| ALEC Alector Inc. | call | Sold out | 500,000 | $1.5Mbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 68 | $2.3B | ERAS, ABVX, RVMD, IDYA, BNTX |
| Q1 2026 | 63 | $1.9B | RVMD, ERAS, IDYA, PRAX, CNTA |
| Q4 2025 | 63 | $1.5B | RVMD, PRAX, IDYA, OLMA, CDTX |
| Q3 2025 | 52 | $1.0B | RVMD, IDYA, AKRO, ARVN, OCUL |
| Q2 2025 | 44 | $748.6M | IDYA, AKRO, RVMD, JAZZ, IRON |
| Q1 2025 | 38 | $562.5M | IDYA, RVMD, AKRO, JANX, NUVL |
| Q4 2024 | 46 | $854.6M | IDYA, JANX, RVMD, CYTK, VERA |
| Q3 2024 | 53 | $892.7M | IDYA, GPCR, RVMD, IRON, JANX |
| Q2 2024Amended | 50 | $867.8M | IDYA, ARGX, MRUS, RVMD, GPCR |
| Q1 2024 | 49 | $950.2M | IDYA, IMCR, IMVT, OCUL, SRPT |